Evidence map›Paper›PMID 26653875›Full record

ReviewNanomedicine (London, England)2016

The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

Claudia Corbo, Roberto Molinaro, Alessandro Parodi, Naama E Toledano Furman, Francesco Salvatore, Ennio Tasciotti

Open access · greenAbstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
241citing papers in PubMed, 1 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

241 citing papers in PubMed, 1 synthesis or guideline pooled it, 668 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

181 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Claudia CorboDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA.
Roberto MolinaroDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA.
Alessandro ParodiDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA.
Naama E Toledano FurmanDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA.
Francesco SalvatoreCEINGE, Advanced Biotechnology s.c.a.r.l., Via G. Salvatore 486, 80145 Naples, Italy.
Ennio TasciottiDepartment of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA.
Houston Methodist · USCeinge Biotecnologie Avanzate (Italy) · IT

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
Leukocyte Membrane Cloaked Carriers to Target and Overcome Tumor VasculatureR21CA173579 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI TASCIOTTI, ENNIO · 2013 to 2014
$371k
NCI NIH HHS 1R21CA173579-01A1NCI NIH HHS 5U54CA143837NCI NIH HHS R21 CA173579NCI NIH HHS U54 CA143837
6 · The paper itself

Abstract

In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue. The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner. However, once injected in a physiological environment, NPs interact with biological components and are surrounded by a protein corona (PC). This can trigger an immune response and affect NP toxicity and targeting capabilities. In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.

Indexed as

AnimalsComplement ActivationDrug Delivery SystemsHumansNanoparticlesimmune responsenano–bio interfacenanomedicinenanoparticlesprotein coronatargetingtoxicity

Identifiers

PMID26653875
PMCPMC4910943
OpenAlexW2194502287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.